BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Novartis Oncology 



East Hanover  New Jersey    U.S.A.
Phone: 888-NOW-NOVA Fax:


SEARCH JOBS




Industry
Healthcare

Segment
Oncology





 Company News
Health Canada Approves Novartis Oncology (NVS)'s AFINITOR for Breast Cancer 1/16/2013 7:36:34 AM    More...
ASA404 to Feature in Novartis Oncology (NVS) Pipeline Update and at San Antonio Breast Cancer Symposium 12/9/2009 10:30:49 AM    More...
Newly Published Phase III Data Show Novartis Oncology (NVS) (JOBS) Drug Sandostatin(R) LAR Depot Reduced Risk of Disease Progression by 66% in Advanced NET Patients 10/1/2009 6:40:31 AM    More...
Novartis Oncology (NVS): Afinitor(R) (everolimus) Now Licensed in UK for Advanced Kidney Cancer Patients After Failure of First Line Vascular Targeted Therapy(1, 2) 9/25/2009 11:07:39 AM    More...
Novartis Oncology (NVS)'s Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery 5/8/2009 11:55:46 AM    More...
Novartis Oncology (NVS) Release: Newly Published Study Reveals Femara(R) Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women 4/30/2007 1:50:04 PM    More...
NICE Initial Recommendation: One Step Closer To Backing Aromatase Inhibitor Treatment For Women With Early Breast Cancer 5/23/2006 11:25:33 AM    More...
Novartis Oncology (NVS) Release: Femara Endorsed Post-Surgery For Women With Early Breast Cancer In Scotland...But Women In The Rest Of The UK Must Wait A Further 6 Months 5/8/2006 1:15:03 PM    More...
Novartis Oncology (NVS) Release: New Clinical Data Show Dramatic Benefits Of Femara(R) For Women With Breast Cancer Even After Prolonged Period Of No Anti-Cancer Treatment 12/13/2005 12:22:24 PM    More...
Novartis Oncology (NVS) Release: UK Leads Europe And US In Milestone Post-op Breast Cancer Treatment Decision 12/8/2005 11:06:48 AM    More...
12